Treace Medical Concepts Shatters Q3 Records with Double-Digit Growth and Expanding Market Share
Treace Medical Concepts has shattered records in its third quarter (Q3) performance, driven by double-digit case volume growth and continued market share gains from increasing adoption of its comprehensive portfolio of best-in-class bunion systems. The company's expanding line of new technologies has further solidified its position in the foot and ankle procedures market.
During the quarter, Treace Medical Concepts advanced its strategic priorities with investments in new products, creating opportunities to build on the foundation established by its flagship product, Lapiplasty. The company is now expanding its presence across a broader range of foot and ankle procedures, with expectations that new 2026 product introductions will expand its total addressable market (TAM) by approximately $700 million.
CEO John Treace highlighted the company's growth strategy, which focuses on three key initiatives: leveraging its large existing customer base to drive adoption of newer bunion systems; building upon its leadership position with Lapiplasty by launching new technologies that can make it even more appealing and attract new surgeon users; and expanding product and procedure offerings to expand TAM and grow wallet share.
One notable example of this strategy is the company's success in driving adoption of newer bunion systems, such as Nanoplasty, Percuplasty, and SpeedMTP. These products have shown a substantial opportunity for increased utilization across its existing customer base, with Lapiplasty having established a strong position in the Lapidus fusion segment of the bunion market.
Treace Medical Concepts also narrowed its full-year 2026 revenue guidance to be in the range of $206 million-$210 million, assuming a return to growth in the fourth quarter through continued procedure volume increases and benefits from new product launches. This outlook reflects the company's disciplined expense management and commitment to enhancing its growth trajectory.
The company's focus on expanding its presence across a broader range of foot and ankle procedures has led to expectations that it will expand its TAM by $700 million with new 2026 product introductions. With continued procedure volume increases, benefits from ASP mix shift dynamics related to 2025 product launches, and benefits from new product launches, Treace Medical Concepts is poised for significant growth in the coming years.
CEO John Treace emphasized that the company's approach positions it to enhance its growth trajectory while improving operating performance over time. This strategic focus has allowed the company to leverage its commercial resources to pursue high-impact growth opportunities while maintaining disciplined expense management.
